Who are Ceftazidime± avibactam with fosfomycin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ceftazidime-avibactam-with-fosfomycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ceftazidime± avibactam with fosfomycin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ceftazidime± avibactam with fosfomycin (Ceftazidime± avibactam with fosfomycin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam/beta-lactamase inhibitor combination with fosfomycin. Area: Infectious Disease.

phase 3 Beta-lactam/beta-lactamase inhibitor combination with fosfomycin Penicillin-binding proteins (PBPs), beta-lactamases, and MurA (UDP-N-acetylglucosamine enolpyruvyl transferase) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ceftazidime± avibactam with fosfomycin (Ceftazidime± avibactam with fosfomycin) — Angela HUTTNER. Ceftazidime-avibactam inhibits bacterial cell wall synthesis while avibactam protects against beta-lactamase degradation, and fosfomycin provides additional cell wall disruption through a distinct mechanism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ceftazidime± avibactam with fosfomycin TARGET	Ceftazidime± avibactam with fosfomycin	Angela HUTTNER	phase 3	Beta-lactam/beta-lactamase inhibitor combination with fosfomycin	Penicillin-binding proteins (PBPs), beta-lactamases, and MurA (UDP-N-acetylglucosamine enolpyruvyl transferase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam/beta-lactamase inhibitor combination with fosfomycin class)

Angela HUTTNER · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ceftazidime± avibactam with fosfomycin — Competitive Intelligence Brief. https://druglandscape.com/ci/ceftazidime-avibactam-with-fosfomycin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab